Sign up for our complimentary
weekly e-journal

Main Newsletter
Mastery Series
Therapy Series
 
Bookmark and Share | Print Article | Items for the Week Previous | All Articles This Week | Next
This article originally posted 23 August, 2012 and appeared in  CardiovascularMedicationType 2 DiabetesIssue 640

Death Risk Drops by 50% for Diabetes Patients Using Statins

Type 2 diabetes patients on statin drugs have lower mortality risk....

Advertisement

In randomized clinical trials, involving 5,152 men and women from 66 to 96 years of age statin medications have been shown to reduce the risk of death in people with type 2 diabetes.

Vilmundur Gudnason, MD, PhD, of the University of Iceland, and colleagues wanted to see if statins had the same beneficial effect in observational studies on older people with type 2 diabetes.

They found that type 2 diabetes patients taking statin drugs had a 50 percent lower risk of dying from heart-related causes and a 53 percent lower risk of dying from all causes, compared to those not taking statins.

Among those without diabetes, statin use was associated with 16 percent lower risk of heart-related death and a 30 percent lower risk of death from all causes.

Diabetes patients who used statins had a similar risk of death as the general population without diabetes. In other words, statin use lowered the risk of death to normal levels, rather than the increased risk generally associated with diabetes.

According to the authors, this observational study adds to a body of evidence showing that statin use may be beneficial for people with type 2 diabetes.

The results urgently call for other population-based studies with comparable information to confirm the effect of statin use on death risk in individuals with type 2 diabetes.

BMJ Open August 2012

Advertisement


 

Bookmark and Share | Print | Category | Home

This article originally posted 23 August, 2012 and appeared in  CardiovascularMedicationType 2 DiabetesIssue 640

Past five issues: Issue 747 | Diabetes Clinical Mastery Series Issue 206 | SGLT-2 Inhibitors Special Edition September 2014 | Issue 746 | Diabetes Clinical Mastery Series Issue 205 |

2014 Most Popular Articles:

Abbott Announces Approval of Its New Unique Continuous Glucose Monitor
Posted September 05, 2014
Low Carb Beats Low Fat
Posted September 05, 2014
Diabetic Neuropathy Improved with Vegan Diet
Posted August 22, 2014
CDC: 40% of American Adults Will Develop Diabetes
Posted August 22, 2014
Empagliflozin (Jardiance) SGLT-2 Inhibitor Now Available in Pharmacies
Posted August 29, 2014
Lilly's Basal Insulin Peglispro Demonstrated HbA1c Superiority against Lantus
Posted September 05, 2014
Pistachios Associated with an Improved Metabolic Risk Profile in Prediabetes
Posted August 29, 2014
New Ultra-Rapid-Acting Insulin Formulation
Posted August 22, 2014
CPAP Lowers BP and A1c in Patients with Obstructive Sleep Apnea and Type 2 Diabetes
Posted August 29, 2014
Sensor Implant Measures Blood pH in Type 1 Diabetes
Posted August 29, 2014


Browse by Feature Writer & Article Category.
A. Lee Dellon, MD | Aaron I. Vinik, MD, PhD, FCP, MACP | Beverly Price | Charles W Martin, DD | Derek Lowe, PhD | Dr. Bernstein | Dr. Brian Jakes, Jr. | Dr. Fred Pescatore | Dr. Tom Burke, Ph.D | Eric S. Freedland | Evan D. Rosen | Ginger Kanzer-Lewis | Greg Milliger | Kristina Sandstedt | Laura Plunkett | Leonard Lipson, M.A. | Louis H. Philipson | Maria Emanuel Ryan, DDS, PhD | Marilyn Porter, RD, CDE | Melissa Diane Smith | Michael R. Cohen, RPh, MS, ScD, FASHP | Paul Chous, M.A., OD | Philip A. Wood PhD | R. Keith Campbell, Professor, B.Pharm, MBA, CDE | Sheri R. Colberg PhD | Sherri Shafer | Stanley Schwartz, MD, FACP, FACE | Steve Pohlit | Steven V. Edelman, M.D. | Timothy S. Hollingshead |

Cast Your Vote
Now that once-weekly dulaglutide has been approved, will you be prescribing it?
CME/CE of the Week
William Tamborlane, MD, FAAP, FACE

Category: General Diabetes
Credits:
 .75
Search Articles On Diabetes In Control